Granite Bio
Basel, CH · Founded 2021 · 26 employees on LinkedIn · 5 known investors
Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options. The company is based in Basel, Switzerland, with a pipeline including Minokitug for autoimmune inflammation and GRT-002 for allergy and itch conditions.
Founders & leadership
PL
Patrick LoustauPresident and Chief Executive Officer
Investors · 5
Novartis Venture Fund✓ verifiedBasel · $5M – $25M
Sanofi Ventures✓ verifiedCambridge · $5M
Forbion✓ verifiedNaarden
Versant Ventures✓ verifiedSan Francisco · $250K – $5M
Also in the syndicate · 1
Novartis Venturelead
Funding
SEC filings, press & company announcements$30M disclosed across 1 round · 2025
- $30MSeries AApr 2025 · 3 sources
Forbion (lead), Novartis Venture (lead), Novartis Venture Fund (lead), Sanofi Ventures (lead), Versant Ventures (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Granite Bio do?
- Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options. The company is based in Basel, Switzerland, with a pipeline including Minokitug for autoimmune inflammation and GRT-002 for allergy and itch conditions.
- Who are Granite Bio's investors?
- Granite Bio's investors include Novartis Venture Fund, Sanofi Ventures, Forbion, Versant Ventures.
- How much funding has Granite Bio raised?
- Granite Bio has disclosed $30M raised across 1 round.
- Where is Granite Bio headquartered?
- Granite Bio is headquartered in Basel, CH.